Dr. Anthony Furlan of the Cleveland Clinic Foundation in Ohio said that the rate of blood flow restoration in stroke patients who were randomly assigned to intravenous treatment with desmoteplase was 53.3 percent, compared with 37.5 percent in patients randomly assigned to receive placebo.
Furlan presented results of the Dose Escalation study of Desmoteplase in Acute Ischemic Stroke (DEDAS) at a late-breaking clinical trials session on Friday at the American Stroke Association International Stroke Conference 2005.